Literature DB >> 8889896

Efficacy measures: surrogates or clinical outcomes?

J W Blue, W A Colburn.   

Abstract

Mesh：

Year:  1996        PMID： 8889896     DOI： 10.1002/j.1552-4604.1996.tb04249.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  3 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 3.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.